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Abstract: Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disease of the hair
follicle typically presenting recurrent, painful, and inflamed lesions on the inverse areas of the
body. Although its pathogenesis remains unknown, the immune system appears to play a potential
role. To date, two previous studies have not found any association between the Human Leukocyte
Antigen system (HLA) and HS. In this study we analyzed the HLA-A, -B, -C; and DRB1, -DQA1, and
–DQB1 allele distribution in 106 HS patients and 262 healthy controls from a Caucasian population in
Cantabria (northern Spain). HLA-A*29 and B*50 were significantly more common in HS patients and
A*30 and B*37 in controls, but these associations disappeared after statistical correction. DRB1*07,
DQA1*02, and DQB1*02 were significantly more common in controls (p 0.026, p 0.0012, and p 0.0005,
respectively) and the HLA allele DQB1*03:01 was significantly more common in HS patients (p 0.00007)
after the Bonferroni correction. The DRB1*07~DQA1*02~DQB1*02 haplotype was significantly more
common in controls (p < 0.0005). This is the first study showing an association between HLA-class II
and HS. Our results suggest that HLA-II alleles (DRB1*07, DQA1*02, DQB1*02, and DQB1*03:01) and
the DRB1*07~DQA1*02~DQB1*02 haplotype could influence resistance or susceptibility to HS.
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1. Introduction
Hidradenitis suppurativa (HS), or acne inversa, is a debilitating and recurrent chronic inflammatory
cutaneous disease that usually presents after puberty with painful, inflamed lesions on the apocrine
gland-bearing areas of the body, most commonly the axillae, inguinal, and anogenital regions [1].
HS affects mostly young adults and the female-to-male ratio is approximately 3:1 [2]. The estimated
prevalence of HS in the Spanish population is 1% (about half a million people). Although its
etiopathogenesis remains uncertain, follicular occlusion due to hyperkeratosis is thought to be the
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primary event. Several factors such as cigarette smoking, obesity, diabetes mellitus, ethnicity, stress,
and drugs have been related to an increased predisposition to HS [2–9].
HS has been reported in several members of different generations of various families [10,11].
Moreover, loss-of-function mutations in the genes encoding essential components of the γ-secretase
multiprotein complex (PSEN1, PSENEN, and NCSTN genes) consistent with an autosomal dominant
inheritance model have been reported in affected families [12–15]. The role of bacteria in the
pathogenesis of HS is controversial. It has been suggested that these infectious agents may play a role
in disease progression rather that in the pathogenesis itself [2,16].
The human leukocyte antigen (HLA) system plays a critical role in controlling the immune
response and has been involved in the pathogenesis of many diseases, in particular those involving
autoimmune phenomena [17]. HLA-encoded factors were found to be associated with several
dermatologic diseases, including psoriasis, autoimmune blistering diseases, alopecia areata, dermatitis
herpetiformis, drug-induced cutaneous hypersensitivity, and others [18–22].
To date, only two studies have investigated the potential role of class I and class II HLA in
the pathogenesis of HS, with contradictory findings [23,24]. In 1998, O’Loughlin et al. [23] reported
the distribution of HLA-A and -B antigens in 27 Irish patients with HS using serological methods.
These investigators found an increased frequency of HLA-A1 and HLA-B8 in patients with moderate
and severe clinical disease. Shortly after, Lapins et al. [24] analyzed the frequencies of HLA-A, -B,
and HLA-DR alleles in 42 unrelated Swedish patients with HS and 250 healthy controls. These results
found no association between any HLA alleles and genetic susceptibility to HS. The discrepancies
between the studies may have resulted from limited sample sizes. Many years have passed since any
group has studied the relationship between HLA and HS.
To further investigate the potential implication of the HLA region in susceptibility to HS, we
assessed the distribution of alleles at HLA-A, B, C, DRB1, DQA1, and DQB1 loci in HS patients and
healthy controls from a genetically homogeneous population (Cantabria, northern Spain) [25,26].
The results obtained after analysis of the data of the HLA alleles and haplotypes were used to conduct
a comparison between individuals with increased or reduced susceptibility to HS.
2. Experimental Section
2.1. Subjects
A total of 106 HS patients and 262 healthy blood donors were recruited through a retrospective
case-control study. HS was diagnosed by dermatologists, and all patients fulfilled the established
diagnostic criteria for HS [27]. Neither consanguinity nor relationship existed among patients or healthy
controls. Furthermore, patients with a family history of HS, diabetes mellitus, or other autoimmune
diseases were excluded. The blood donors (mean age, 48 years; range, 18–65 years; male/female ratio,
1:3) and HS patients (mean age, 56 years; range, 23–76 years) were of Caucasian background, all of
them belonging to the Community of Cantabria (northern Spain). No other ethnicities were included
in the patient population. Healthy control blood donors were examined by a dermatologist to rule out
the presence of skin lesions that could bias the study. Procedures used in the study conformed to the
principles outlined in the Declaration of Helsinki. All samples were collected with the written consent
of the participants. The protocol of the study was accepted and approved by the Research Ethics Board
of Hospital Universitario Marqués de Valdecilla.
2.2. HLA Typing
High-molecular-weight DNA samples were prepared from whole blood by using the Maxwell
16 Blood DNA Purification Kit (Promega Biotech Ibérica, S.L., Madrid, Spain). DNA-based HLA
classes I and II typing was performed using sequence-specific oligoprobes in the Luminex 100 system
(Luminex, Austin, TX, USA) and the Lifecodes HLA Typing Kits, and analyzed using the MatchIT
software (Gen-Probe Inc., San Diego, CA, USA) following the manufacturer’s instructions. To confirm
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the results, HLA-DQB1 high-resolution typing was performed through sequencing-based typing (SBT)
using the SBTexcellerator Kit and analyzed with the SBTengine-SBT HLA typing software (GenDx,
Utrecht, The Netherlands).
2.3. Statistical Analysis
HLA allelic frequencies were calculated by direct counting. Haplotype frequencies were analyzed
by the maximum-likelihood method assuming Hardy–Weinberg equilibrium (HWE). Patients and
controls were compared using the two-tailed χ2 test, or the Fisher’s exact test when necessary with Yates’
continuity correction with an α level of 0.05. The p-values and odds ratios (OR) with 95% confidence
intervals (CIs) were calculated using SPSS version 12 (SPSS Inc., Chicago, IL, USA). A p-value < 0.05 was
considered statistically significant. The Bonferroni correction for multiple comparisons was applied to
avoid false positive results. It was calculated by multiplying the initial p-value by the number of HLA
alleles at each locus. A value of p < 0.05 was considered statistically significant. The statistical power of
the study’s sample size was calculated using PS Power and Sample Size Calculations software version
3.0 (NCSS Statistical Analysis & Graphics Software, Kaysville, UT, USA) [28].
3. Results
3.1. HLA-A, -B, and -C Alleles in HS Patients and Controls
All allele and haplotype frequencies were in HWE. The frequencies of HLA-A, -B, and -C alleles
in HS patients and healthy controls are summarized in Table 1. HLA-A*29 was significantly more
common in healthy controls and HLA-A*30 in HS patients (p 0.02, OR 0.44, 95% CI: 0.21–0.91 and
p 0.03, OR 2.20, 95% CI: 1.13–4.28, respectively). HLA-B*37 was also significantly more common in HS
patients and HLA-B*50 in healthy controls (p 0.04, OR 3.64, 95% CI: 1.08–12.24 and p 0.04, OR 0.38,
95% CI: 0.15–0.92, respectively). These associations were no longer significant after performing the
Bonferroni correction.
Table 1. HLA-A (a), -B (b), and -C (c) allele frequencies in HS (Hidradenitis suppurativa) patients and
healthy controls.
(a)
HLA-A HSn = 106
Controls
n = 262 p OR 95% CI
01 19 56 0.57 0.82 0.45–1.42
02 54 132 0.99 1.01 0.70–1.46
03 28 69 0.92 1.00 0.63–1.61
11 8 43 0.05 0.44 0.20–0.95
23 9 19 0.85 1.18 0.52–2.65
24 23 40 0.21 1.47 0.86–2.53
25 8 12 0.38 1.67 0.67–4.15
26 6 16 0.94 0.92 0.36–2.40
29 9 48 0.02 0.44 0.21–0.91
30 17 20 0.03 2.20 1.13–4.28
31 6 13 0.99 1.14 0.43–3.06
32 11 12 0.07 2.33 1.01–5.38
33 5 16 0.79 0.77 0.28–2.12
34 0 1 N/A N/A N/A
66 2 4 1.00 1.37 0.29–6.50
68 5 22 0.28 0.59 0.23–1.52
80 2 1 0.20 4.14 0.54–31.58
Total * 212 524
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Table 1. Cont.
(b)
HLA-B HSn = 106
Controls
n = 262 p OR 95% CI
07 26 57 0.65 1.16 0.71–1.89
08 8 30 0.41 0.67 0.31–1.47
13 2 12 0.37 0.49 0.12–1.91
14 9 31 0.52 0.73 0.35–1.54
15 15 41 0.89 0.91 0.50–1.68
18 13 20 0.22 1.67 0.82–3.37
27 4 20 0.25 0.53 0.19–1.49
35 18 53 0.63 0.84 0.48–1.46
37 6 4 0.04 3.64 1.08–12.24
38 6 6 0.17 2.51 0.84–7.54
39 1 3 1.00 1.06 0.16–7.20
40 8 18 0.93 1.14 0.50–2.61
41 2 4 1.00 1.37 0.29–6.50
44 29 104 0.06 0.65 0.42–1.01
45 5 6 0.31 2.11 0.67–6.66
49 6 17 0.97 0.91 0.37–2.28
50 9 10 0.04 0.38 0.15–0.92
51 23 41 0.22 1.44 0.85–2.46
52 1 7 0.45 0.49 0.08–2.85
53 9 10 0.11 2.29 0.94–5.58
55 4 8 0.75 1.31 0.41–4.16
56 1 2 1.00 1.48 0.19–11.29
57 4 14 0.79 0.76 0.26–2.21
58 2 6 1.00 0.95 0.22–4.11
81 1 0 N/A N/A N/A
Total * 212 524
(c)
HLA-C HSn = 106
Controls
n = 262 p OR 95% CI
01 8 18 0.99 1.10 0.47–2.58
02 9 36 0.24 0.60 0.28–1.27
03 16 48 0.58 0.81 0.45–1.46
04 43 75 0.06 1.52 1.01–2.31
05 17 37 0.77 1.15 0.63–2.09
06 17 36 0.70 1.18 0.65–2.15
07 51 134 0.73 0.92 0.64–1.34
08 9 28 0.66 0.79 0.36–1.69
12 11 26 0.95 1.05 0.51–2.16
14 6 6 0.19 2.51 0.80–7.89
15 11 26 0.95 1.05 0.51–2.16
16 11 50 0.07 0.52 0.26–1.02
17 2 4 1.00 1.24 0.23–6.81
18 1 0 N/A N/A N/A
Total * 212 524
Note: p-values were not corrected for multiple comparisons. Antigens with statistically significant differences
between the two groups are in bold. After the Bonferroni correction, significant p-values disappeared. * Note that
total count is double the number of individuals due to the presence of two alleles.
3.2. HLA-DRB1, -DQA1, and -DQB1 Alleles and Haplotypes in HS Patients and Controls
The examination of the distribution of HLA class II alleles showed that the allele groups including
DRB1*07, DQA1*02, and DQB1*02 alleles were significantly more common in healthy controls (p 0.002,
OR 0.45, 95% CI: 0.27–0.74; p 0.0002, OR 0.43 95% CI: 0.28–0.67; and p 0.0001, OR 0.44, 95% CI: 0.27–0.67,
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respectively; Table 2). These associations remained statistically significant after the Bonferroni correction
(p 0.026, 0.0012, and 0.0006, respectively).
Table 2. HLA-DRB1 (a), -DQA1 (b), and -DQB1 (c) allele frequencies in HS patients and healthy controls.
(a)
HLA-DRB1 HSn = 106
Controls
n = 262 p OR 95% CI
01 25 68 0.75 0.90 0.55–1.46
03 13 52 0.13 0.59 0.32–1.11
04 33 62 0.21 1.37 0.87–2.17
07 21 103 0.002 0.45 0.27–0.74
08 10 19 0.63 1.31 0.60–2.88
09 1 5 0.68 0.49 0.06–4.24
10 3 6 0.72 1.24 0.31–5.00
11 31 49 0.05 1.66 1.03–2.69
12 2 6 1.00 0.95 0.22–4.11
13 38 74 0.24 1.33 0.87–2.04
14 6 10 0.62 1.50 0.54–4.17
15 26 62 0.97 1.04 0.64–1.70
16 3 8 1.00 0.93 0.24–3.52
Total 212 524
(b)
HLA-DQA1 HSn = 106
Controls
n = 262 p OR 95% CI
01 96 222 0.52 1.13 0.82–1.55
02 21 102 0.0002 0.43 0.28–0.67
03 33 75 0.75 1.10 0.71–1.72
04 8 15 0.68 1.33 0.56–3.19
05 52 109 0.31 1.24 0.85–1.80
06 2 1 0.20 4.98 0.45–55.22
Total 212 524
(c)
HLA-DQB1 HSn = 106
Controls
n = 262 p OR 95% CI
02 29 141 0.0001 0.44 0.27–0.67
03 78 145 0.02 1.52 1.08–2.13
04 9 16 0.56 1.41 0.61–3.24
05 42 95 0.67 1.12 0.74–1.67
06 54 127 0.80 1.07 0.74–1.54
Total 212 524
Note: p-values were not corrected for multiple comparisons. After the Bonferroni correction, significant p-values
remained significant except for DQB1*03 (DRB1*07 p = 0.026, DQA1*02 p = 0.0012, and DQB1*02 p = 0.0005).
In contrast, the allele group HLA-DQB1*03 was statistically more common in HS patients
(p 0.02, OR 1.52 95% CI 1.08–2.13). This was especially true for the HLA-DQB1*03:01 allele, which
was significantly more common in HS patients than healthy controls (p 0.00001, OR 2.33, 95% CI:
1.57–3.44), with a statistical power >90% (Table 3a). Other DQB1*03 alleles did not show significant
differences. When the various DQA1 alleles in linkage disequilibrium with DQB1*03:01 in the study’s
population (DQA1*03, *05, and *06) were analyzed, the HLA DQA1*03–DQB1*03:01 and the HLA
DQA1*05–DQB1*03:01 haplotype blocks, assigned by linkage disequilibrium, showed statistically
significant differences in HS patients and healthy controls (p 0.01 and 0.004, respectively; Table 3b),
but with lower p-values than observed for individual allele DQB1*03:01. The combination of both
haplotype blocks showed higher significance (p 0.0001, OR 2.25, 95% CI 1.52–3.34) than that observed
in the individual DQA1-DQB1 blocks bearing DQB1*03:01 with a statistical power >80%.
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Table 3. Distribution of DQB1*03:01 allele in HS patients and healthy controls and analysis of the
DQB1*03:01 frequencies found in the different heterodimer molecules.
(a)
DQB1*03:01 HS n = 106 Controls n = 262 p OR 95% CI
58 73 0.00001 2.33 1.57–3.44
TOTAL 212 524
(b)
DQα DQβ HS n = 106 Controls n = 262 p OR 95% CI
03 03:01 15 14 0.01 2.77 1.31–5.85
05 03:01 41 58 0.004 1.92 1.24–2.98
06 03:01 2 1 0.20 4.80 0.45–55.22
In (a), the difference in the frequency of the DQB1*03:01 allele between the two groups reached a statistical power
of 98%. In (b), only heterodimerization between DQα03/DQβ03:01 and DQα05/DQb03:01 showed statistical
significance (p = 0.03 and 0.012 after the Bonferroni correction, respectively).
The analysis of the different haplotype blocks showed a significant increase in the
DRB1*07–DQA1*02–DQB1*02 haplotype in controls (p 0.0014 OR 0.39 95% CI 0.23–0.70); this association
remained significant after the Bonferroni correction (p 0.028, Table 4).
Table 4. Frequency of the HLA DRB1*07–DQBA1*02–DQB1*02 haplotype in HS patients and controls.
DRB1*07–DQA1*02–DQB1*02 HSn = 106
Controls
n = 262 p OR 95% CI
16 89 0.0014 0.40 0.23–0.70
Total 212 524
After correction for multiple comparisons, p-value remained significant (p 0.028). The comparison included all the
DRB1*07–DQA1*02–DQB1*02 haplotypes found in the current study.
4. Discussion
This study involved the largest HS patient group assessed to identify a potential association
with the HLA region. The pathophysiology of HS is still not well understood [1,2]. Epidemiological
studies suggest the influence of many genetic and environmental factors. In addition to family
cases due to mutations in genes encoding essential components of the γ-secretase multiprotein
complex (PSEN1, PSENEN, and NCSTN genes) [12–15], several other factors including psychological
influences, metabolism, smoking habits, bacterial infections, and associations with other diseases
(mainly inflammatory disorders) have been related to a higher incidence of HS [1–9,16,29]. Recently,
our group reported on the role of several adipokines (adiponectin, leptin, resistin, and visfatin) in
patients with HS and investigated the possible associations with insulin resistance, HS risk, and
disease severity [30]. The role of the immune system in the etiopathogenesis of HS has yet to be
elucidated. Several reports have focused on the role of immune dysregulation with complement
abnormalities [31,32]. Recently, innate immunity, auto-inflammatory mechanisms, and distribution
of certain T-cell lymphocyte subpopulations have been shown to influence the pathophysiology of
HS [33–35].
There was limited evidence, if any, regarding the role of HLA factors in susceptibility and resistance
to HS before this study. No study addressed the possible influence of the HLA region in susceptibility
to and protection against HS since 2001 [24]. No association of HLA-A, -B, and -DRB1 alleles and HS
was found in 42 unrelated Swedish patients with HS compared to 250 controls. Similar results were
found in a study of the implication of the HLA-A and HLA-B antigen loci in 27 Irish patients with
untreated HS compared to 20 healthy blood donors without relevant differences [23].
We analyzed the phenotype distributions of alleles for the first time, encoding six HLA loci
(HLA-A, -B, -C, -DRB1, -DQA1, and -DQB1) in 106 HS patients and 262 healthy blood donors from a
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condensed population (Cantabria, northern Spain). The results that showed weak effects of alleles at
HLA-A and -B loci were no longer significant after statistical correction. In contrast, alleles at class II
loci showed statistically significant differences in the distribution of allele groups DRB1*07, DQA1*02,
and DQB1*02, being significantly less common in HS patients. These alleles are in strong linkage
disequilibrium, conforming to a common and extremely well-conserved haplotype block that was
less common in the patient group and suggesting a protective role against the development of the
disease. Because of the strong linkage disequilibrium, it was not possible to pinpoint which factor of
this DRB1-DQ block confers protection.
Even more relevant than the evidence of protective alleles was the presence of the association
between the HLA-DQB1*03 group—the DQB1*03:01 allele in particular—and susceptibility to HS in
Caucasian patients from northern Spain. A comparison of the amino acid sequences of the common
alleles of DQB1*03 (03:01, 03:02, and 03:03) showed that specific amino acid replacements at residue 45
and possibly residue 57 may determine the differential associations between alleles in this group.
In the study population, DQB1*03:01, as in most European populations, was found in association
with several alleles of DQA1 and DRB1 loci. The highest statistically significant association of
HLA alleles present in haplotype blocks bearing DQB1*03:01 was observed for this allele, with no
association observed for DRB1 alleles and weak associations for DQA1 alleles. The allele DQB1*03:01
allele may form heterodimer molecules when pairing with the alleles DQA1*03, *05, and *06 alleles.
Only DQB1*03:01 heterodimers with DQA1*03 and *05 showed significant differences between HS
patients and controls. Whether the DQB1 locus alone could explain most of the risk in our cohort of HS
patients, as has been suggested in other pathologies such as narcolepsy [36–38] or DQ heterodimerization
of DQα03/DQβ03:01 and DQα05/DQβ03:01, and therefore, the risk of the HLA-DQB1*03:01 gene, has to
be considered alongside its polymorphic partners HLA-DQA1*03 and *05 and would need additional,
larger studies.
Interestingly, DQB1*03:01 has been reported as a susceptibility allele in another dermatological
disease: bullous pemphigoid, an organ-specific autoantibody-mediated autoimmune blistering skin
disorder in normal patients and in type 2 diabetes mellitus patients receiving dipeptidyl peptidase-IV
inhibitors [22,39–42]. The mechanism of this association is still unclear, but it has been proposed that
DQB1*03:01 could bind bullous pemphigoid 180 (BP180, BP antigen 2, collagen XVII), which may lead
to cutaneous disease [42–44].
The limited patient population may be a potential limitation for the study. However, our study
has a number of strengths. It encompassed, to the best of our knowledge, the largest series of HS
patients ever evaluated for genetic susceptibility. Moreover, it had a monocentric design with the
inclusion of patients homogeneously and carefully evaluated by a group of clinicians with extensive
experience with the disease. However, additional studies in Caucasians and other populations should
be conducted to further support the influence of HLA in conferring susceptibility to this disease.
5. Conclusions
As observed in other inflammatory chronic diseases such as rheumatoid arthritis [45], this study
showed for the first time a relevant contribution of HLA class II alleles and haplotypes to protection
against and susceptibility to HS. Our findings open new avenues for investigating the role of HLA
factors in the mechanisms leading to the development of this disease that affects more than 500,000
people in the Spanish population.
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